Bb Biotech Ag Buys Myovant Sciences, Macrogenics, Juno Therapeutics, Sells Cempra, PTC Therapeutics

Feb 15, 2017

Schaffhausen, V8, based Investment company Bb Biotech Ag buys Myovant Sciences, Macrogenics, Juno Therapeutics, Cidara Therapeutics, sells Cempra, PTC Therapeutics during the 3-months ended 2016-12-31, according to the most recent filings of the investment company, Bb Biotech Ag. As of 2016-12-31, Bb Biotech Ag owns 29 stocks with a total value of $2.7 billion. These are the details of the buys and sells.

New Purchases: MYOV,
Added Positions: MGNX, JUNO, AGIO, ALXN, ITCI, CDTX, HALO,
Reduced Positions: IONS, PTCT,
Sold Out: CEMP,

For the details of BB BIOTECH AG's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=BB+BIOTECH+AG

These are the top 5 holdings of BB BIOTECH AG

Celgene Corp (CELG) - 3,459,298 shares, 14.83% of the total portfolio.
Incyte Corp (INCY) - 3,879,822 shares, 14.41% of the total portfolio.
Ionis Pharmaceuticals Inc (IONS) - 6,913,172 shares, 12.25% of the total portfolio. Shares reduced by 3.49%
Gilead Sciences Inc (GILD) - 2,774,596 shares, 7.36% of the total portfolio.
Radius Health Inc (RDUS) - 4,360,399 shares, 6.14% of the total portfolio.

New Purchase: Myovant Sciences Ltd (MYOV)

Bb Biotech Ag initiated holdings in Myovant Sciences Ltd. The purchase prices were between $10.45 and $14.25, with an estimated average price of $11.59. The stock is now traded at around $11.24. The impact to the portfolio due to this purchase was 1.47%. The holdings were 3,192,835 shares as of 2016-12-31.

Added: Macrogenics Inc (MGNX)

Bb Biotech Ag added to the holdings in Macrogenics Inc by 31.96%. The purchase prices were between $18.36 and $30.95, with an estimated average price of $25.17. The stock is now traded at around $19.55. The impact to the portfolio due to this purchase was 0.35%. The holdings were 1,920,000 shares as of 2016-12-31.

Added: Juno Therapeutics Inc (JUNO)

Bb Biotech Ag added to the holdings in Juno Therapeutics Inc by 33.10%. The purchase prices were between $17.86 and $32.97, with an estimated average price of $24.47. The stock is now traded at around $23.51. The impact to the portfolio due to this purchase was 0.33%. The holdings were 1,870,000 shares as of 2016-12-31.

Added: Cidara Therapeutics Inc (CDTX)

Bb Biotech Ag added to the holdings in Cidara Therapeutics Inc by 39.77%. The purchase prices were between $8.7 and $11.55, with an estimated average price of $10.39. The stock is now traded at around $11.43. The impact to the portfolio due to this purchase was 0.11%. The holdings were 1,043,824 shares as of 2016-12-31.

Sold Out: Cempra Inc (CEMP)

Bb Biotech Ag sold out the holdings in Cempra Inc. The sale prices were between $2.6 and $23.97, with an estimated average price of $12.13.

Here is the complete portfolio of BB BIOTECH AG. Also check out:

1. BB BIOTECH AG's Undervalued Stocks
2. BB BIOTECH AG's Top Growth Companies, and
3. BB BIOTECH AG's High Yield stocks
4. Stocks that BB BIOTECH AG keeps buying

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.